Executive leadership New CEO appointment signals strategic direction and potential shifts in product partnerships and funding approach. Engage Dan Brounstein to explore collaboration on near-term clinical trials and commercialization plans.

Funding momentum Recent Series A funding and ongoing investor support indicate strong growth trajectory and potential for strategic partnerships, co-development, or pilot programs with larger medical device players.

Clinical focus Specialization in minimally invasive neuromodulation for obstructive sleep apnea positions Avivomed to target sleep medicine and ENT channels, suggesting opportunities with hospital systems, sleep clinics, and payer-aligned trial sites.

Technology stack Cloud and cloud-based collaboration tools combined with a scalable digital presence offer avenues for remote monitoring device ecosystems, data partnerships, and compliance-ready cloud data services with potential OEM integrations.

Financial potential Revenue range and compact team imply room for scalable partnerships with established device manufacturers for co-development, distribution agreements, or licensing of neuromodulation platform components.